BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 37195589)

  • 1. Update on Small Molecule Targeted Therapies for Acute Myeloid Leukemia.
    Wang J; Tomlinson B; Lazarus HM
    Curr Treat Options Oncol; 2023 Jul; 24(7):770-801. PubMed ID: 37195589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel Targeted Therapeutics in Acute Myeloid Leukemia: an Embarrassment of Riches.
    Grieselhuber NR; Mims AS
    Curr Hematol Malig Rep; 2021 Apr; 16(2):192-206. PubMed ID: 33738705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging Targeted Therapy for Specific Genomic Abnormalities in Acute Myeloid Leukemia.
    Chi SG; Minami Y
    Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Relapsed/Refractory Acute Myeloid Leukemia.
    Bose P; Vachhani P; Cortes JE
    Curr Treat Options Oncol; 2017 Mar; 18(3):17. PubMed ID: 28286924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations.
    Shoukier M; Kadia T; Konopleva M; Alotaibi AS; Alfayez M; Loghavi S; Patel KP; Kanagal-Shamanna R; Cortes J; Samra B; Jabbour E; Garcia-Manero G; Takahashi K; Pierce S; Short NJ; Yilmaz M; Sasaki K; Masarova L; Pemmaraju N; Borthakur G; Kantarjian HM; Ravandi F; DiNardo CD; Daver N
    Cancer; 2021 Feb; 127(3):381-390. PubMed ID: 33119202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Olutasidenib: a novel mutant IDH1 inhibitor for the treatment of relapsed or refractory acute myeloid leukemia.
    Cortes JE
    Expert Rev Hematol; 2024 Jun; 17(6):211-221. PubMed ID: 38747392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging small molecular inhibitors as targeted therapies for high-risk acute myeloid leukemias.
    Sahasrabudhe KD; Albrethsen M; Mims AS
    Expert Rev Hematol; 2023; 16(9):671-684. PubMed ID: 37405412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute Myeloid Leukemia Treatment in the Elderly: A Comprehensive Review of the Present and Future.
    Choi JH; Shukla M; Abdul-Hay M
    Acta Haematol; 2023; 146(6):431-457. PubMed ID: 37459852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IDH Inhibitors in AML-Promise and Pitfalls.
    McMurry H; Fletcher L; Traer E
    Curr Hematol Malig Rep; 2021 Apr; 16(2):207-217. PubMed ID: 33939107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances in targeted therapies in acute myeloid leukemia.
    Bhansali RS; Pratz KW; Lai C
    J Hematol Oncol; 2023 Mar; 16(1):29. PubMed ID: 36966300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.
    Paschka P; Schlenk RF; Gaidzik VI; Habdank M; Krönke J; Bullinger L; Späth D; Kayser S; Zucknick M; Götze K; Horst HA; Germing U; Döhner H; Döhner K
    J Clin Oncol; 2010 Aug; 28(22):3636-43. PubMed ID: 20567020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New Treatment Options for Acute Myeloid Leukemia in 2019.
    Cerrano M; Itzykson R
    Curr Oncol Rep; 2019 Feb; 21(2):16. PubMed ID: 30715623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Updates on targeted therapies for acute myeloid leukaemia.
    Kayser S; Levis MJ
    Br J Haematol; 2022 Jan; 196(2):316-328. PubMed ID: 34350585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of Relapsed Acute Myeloid Leukemia.
    Thol F; Ganser A
    Curr Treat Options Oncol; 2020 Jun; 21(8):66. PubMed ID: 32601974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia.
    Luskin MR; DeAngelo DJ
    Expert Rev Hematol; 2017 Dec; 10(12):1033-1045. PubMed ID: 29069942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecularly targeted therapy in acute myeloid leukemia.
    Gill H; Leung AY; Kwong YL
    Future Oncol; 2016 Mar; 12(6):827-38. PubMed ID: 26828965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of FLT3 and IDH1/2 inhibitors in patients with acute myeloid leukemia previously treated with venetoclax.
    Bewersdorf JP; Shallis RM; Derkach A; Goldberg AD; Stein A; Stein EM; Marcucci G; Zeidan AM; Shimony S; DeAngelo DJ; Stone RM; Aldoss I; Ball BJ; Stahl M
    Leuk Res; 2022 Nov; 122():106942. PubMed ID: 36108424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging FLT3 inhibitors for the treatment of acute myeloid leukemia.
    Solana-Altabella A; Ballesta-López O; Megías-Vericat JE; Martínez-Cuadrón D; Montesinos P
    Expert Opin Emerg Drugs; 2022 Mar; 27(1):1-18. PubMed ID: 35076348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New agents for the treatment of acute myeloid leukemia.
    Tallman MS
    Best Pract Res Clin Haematol; 2006; 19(2):311-20. PubMed ID: 16516128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Experimental drugs in clinical trials for acute myeloid leukemia: innovations, trends, and opportunities.
    Gołos A; Góra-Tybor J; Robak T
    Expert Opin Investig Drugs; 2023 Jan; 32(1):53-67. PubMed ID: 36669827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.